

Part VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for Loperamid ABECE 2 mg tabletter, Loperamid NET 2 mg tabletter, Loperamid Apofri 2 mg tabletter and Loperamid Norfri 2 mg tabletter

This is a summary of the risk management plan for Loperamid ABECE 2 mg tabletter, Loperamid NET 2 mg tabletter, Loperamid Apofri 2 mg tabletter and Loperamid Norfri 2 mg tabletter (hereafter referred to as loperamide tablets). The RMP details important risks of the medicinal product, how these risks can be minimised, and how more information will be obtained about loperamide tablets risks and uncertainties (missing information).

Loperamid tablet's Summary of Product Characteristics (SmPC) and its Package Leaflet give essential information to healthcare professionals and patients on how the loperamide tablets should be used.

Important new concerns or changes to the current ones will be included in updates of loperamid tablet's RMP.

I. The medicine and what it is used for

Loperamid ABECE 2 mg tabletter, Loperamid NET 2 mg tabletter and Loperamid Apofri 2 mg tabletter are authorised for the symptomatic treatment of acute nonspecific diarrhoea and chronic diarrhoea conditions including excessively rapid intestinal passage, with or without faecal incontinence and in association with ileostomies, colostomies and dumping.

Loperamid Norfri 2 mg tablet is authorised for the symptomatic treatment of acute nonspecific and chronic diarrhoea conditions. For excessively rapid intestinal passage after gastric resection. They contain loperamide hydrochloride as the active substance and can be given by oral route of administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Loperamide tablets, together with measures to minimise such risks and the proposed studies for learning more about Loperamide tablet's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;

- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Loperamide tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of the medicinal product. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<i>List of important risks and missing information</i>	
Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned with the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Loperamide tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Loperamide tablets.